DPP4 and Stroke: A large, nationwide cohort study involving 113,051 patients with diabetes demonstrated that the use of DPP-4 inhibitors as a second-line add-on to metformin was associated with significantly lower risks of stroke, major adverse cardiovascular events (MACEs), and all-cause mortality when compared to sulfonylurea-based regimens.